schizophrenia therapeutics / Boehringer Ingelheim, Saniona - LARVOL DELTA

Establishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia: Two Exploratory Single-Arm Studies. (PubMed, JMIR Ment Health) - P=N/A | "A positive DWA was established between participants and CT-155 beta within 3 weeks. The second 7-week study showed maintenance of the DWA to the end of the study. Results support the establishment and maintenance of a DWA between adults with ENS of schizophrenia and a beta version of CT-155/BI 3972080, a prescription digital therapeutic under development to target these symptoms."

Journal • CNS Disorders • Psychiatry • Schizophrenia